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patients, and the physical symptoms that often accompany
depression may predict treatment resistance and a worse outcome.
If so, this may have important clinical implications. The aim of this
systematic review was to explore the association of concomitant
physical symptoms with the outcome of major depressive disorder
(MDD).Methods: Systematic review: Medline, Psychinfo, and the
Cochrane Library were searched for prospective, cross-sectional,
and retrospective studies, and also for open-label trials and
randomized controlled trials. The risk of bias assessment and data
extraction were performed in duplicate. A qualitative best-evidence
synthesis was performed, based on the number of studies reporting
on the association between physical symptoms and the course of⁎ Corresponding author. Department of Diagnosis and Treatment,
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doi:10.1016/j.jpsychores.2009.11.009MDD, the consistency of the results, and the methodological
quality. The findings were reported according to the PRISMA
guidelines. Results: Nine studies met the inclusion criteria.
Although the design, outcome measures, and data presentation
varied too much to make statistical pooling possible, the best
evidence synthesis resulted in strong, consistent evidence for a
negative association between physical symptoms and the course of
MDD. Conclusion: This systematic review shows a negative
association of concomitant physical symptoms with the course of
MDD. The effect might be considerable, but the number of studies
addressing this topic is small and there was a wide variation in the
study designs and outcome measures. More research is needed.
© 2010 Elsevier Inc. All rights reserved.Keywords: Depression; Comorbidity; Effect modifiers (epidemiology); Somatisation; Systematic review; Physical symptomsIntroduction
The Global Burden of Disease Study, carried out by the
WHO, reports that major depressive disorder (MDD) is
expected to be the second leading cause of disability-adjusted
life-years in 2020 [1]. Both psychological and pharmaco-
logical interventions are effective in the treatment ofMDD, but like in other fields of medicine, efficacy trials
where it is possible to control certain conditions, do not
always produce the same results as effectiveness trials in real
world settings [2]. Results from the STAR*D study, for
instance, show that remission rates in response to treatment
with a selective serotonin reuptake inhibitor (SSRI) are as low
as 26.6% in primary care [3]. These rates improve after
subsequent treatment steps, but remission is not easily
achieved [4]. This might lead to unnecessary suffering and
high costs for society [5,6].
MDD may be difficult to treat in everyday practice, as a
result of concomitant physical symptoms interfering with
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many physical symptoms may be less motivated to undergo
treatment. This is an important subject for study, in view of
the frequent co-occurrence of physical symptoms and
MDD. Studies in primary care, for instance, have found
that up to 70% of MDD patients only report physical
symptoms when first presenting to a general practitioner [7].
Moreover, a recent study [8] reported that it is 4.43 times
more likely for a depressed patients to have a somatoform
disorder than for patient who is not depressed (confidence
interval: 2.73–7.19).
Examples of symptoms that often co-occur with MDD
are pain, fatigue, disturbed sleep, indigestion, dizziness, and
fainting [9,10]. The more of these symptoms a patient
experiences, the greater the probability that he or she is also
suffering from a depressive disorder [9,10]. The importance
of physical symptoms in patients suffering from MDD will
also be recognized by clinicians, many of whom find
patients with physical comorbidity difficult to treat. A
recent systematic review provided evidence that pain
predicts a longer time to remission in patients suffering
from MDD [11].
To our knowledge, evidence with regard to the prognostic
effect of the wider spectrum of concomitant physical
symptoms—not restricted to pain—on the course of MDD
has not yet been reviewed. Identifying factors that may
predict treatment resistance or poor outcome are important,
both for the education of patients and the selection of
appropriate treatment. We therefore conducted a systematic
review of studies that assessed the associations between
physical symptoms and the prognosis of MDD. The
association in terms of prognostic value in cohort studies,
as well as the modification of treatment effect in trials can
provide valuable information about this topic. Both types of
studies were therefore included.Method
Information sources and eligibility criteria
The search was performed in Medline, Psychinfo, and the
database of the Cochrane Collaboration. The search focused
on retrospective and prospective designs, as well as on open-
label trials and randomized controlled trials. Studies had to
meet the following criteria in order to be included:
1. At baseline, an assessment had to be made to determine
whether patients were suffering from MDD. There was
no restriction as to how MDD was diagnosed. At
follow-up, an assessment had to be made about the
outcome of the disorder. This could include clinical
outcomes such as symptom reduction on a scale
measuring depressive symptoms, response in terms of
a decrease of a certain percentage on a scale measuring
depressive symptoms, and time to such a response.It could also include process measures such as
treatment adherence.
2. An assessment of physical symptoms had to be
included at baseline. Since this review focused on a
wider spectrum of physical symptoms than just one
individual symptom, such as pain, special attention
was paid to the way in which these symptoms were
identified. The assessment of physical symptoms at
baseline could not be limited to just one symptom.
Furthermore, the studies had to include either:
(a) a validated (sub-)scale to measure physical
symptoms
(b) information about physical symptoms from med-
ical records
(c) an assessment of physical symptoms by a medical
practitioner.
With regard to the sub-criterion (a) (validated
measures), we decided that the anxiety/somatization
sub-scale of the Hamilton Depression Inventory
17-item version (HAMD-17) [12] could not be used
as a valid measure of physical symptoms for the
purpose of our review. This sub-scale consists of six
items that reflect on both psychological and somatic
symptoms of depression and anxiety. Therefore,
studies had to use some other instrument to assess
physical symptoms.
3. Studies had to report sufficient information on the
association between physical symptoms and the
outcome or course of MDD, expressed as odds ratios
(OR), relative risks (RR), beta-coefficients (β), hazard
ratios (HR), effect sizes, or mean differences.
Search
The exact keywords and Mesh-terms are available upon
request. Briefly, we combined multiple keywords and
medical subject headings (Mesh-terms) for MDD with
multiple keywords regarding information on the outcome or
course of the disorder and keywords referring to the design of
the study. Finally, 102 symptoms and symptom-related
keywords were added to the search, ranging from pain and
fatigue to somatoform disorders or somatization, and
including symptoms such as headache, nausea, and gas. Our
search strategy is described in more detail in the Appendix.
The following searches were conducted:
• Medline was searched from its onset to November 24,
2008. There was no restriction as to the publication date
of a study. The searches in Medline were periodically
updated after the 24th of November 2008, but no
additional papers were identified before submission of
this document. There was no language restriction
included in the search.
• Psychinfo was searched until March 25, 2009. Again,
there was no restriction with regard to publication date
or language.
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March 25, 2009. Again, there was no restriction with
regard to publication date or language.
Study selection, risk of bias assessment, and data
collection process
All titles and abstracts (N=2327) were read by one of
the authors (K.H.). Full-text publications of studies that
were potentially eligible for inclusion (N=82) were read by
two reviewers (K.H. and C.F.C.). They both checked the
criteria for eligibility. Consensus was reached in all cases.
In this stage, the quality of the papers was not assessed.
Nine papers met the eligibility criteria. These were
included in the review and were submitted to full quality
assessment, performed independently by two assessors
(K.H. and C.F.C.) who were unaware of each other's
assessments. The studies were assessed according to a list
of predefined criteria described in a systematic review [13].
This checklist is based on previously used validity
checklists [14], theoretical considerations, and methodo-
logical aspects of prognostic research [15,16]. Any
disagreements among the reviewers were resolved byFig. 1. Study sasking a third independent assessor (HvM) to assess the
study on the criterion that caused disagreement. In all cases
consensus was reached. The list of criteria is described in
the first column of Table 2. A study was considered to be
of high quality if 60% or more of the quality criteria were
met (10 or more criteria out of 16).
Data were extracted on changes in the severity of
depressive symptoms and the association of this outcome
with physical symptoms. The type of association varied
among the studies and could be presented as ORs,
regression coefficients, correlation coefficients, or mean
changes. Data were also extracted on the design of the
study, the setting, the characteristics of the study popula-
tion, the treatment of depression, and the duration of the
follow-up.
Data-extraction was performed independently, and in
duplicate, by two members of the research group (K.H.
and C.F.C.).
Synthesis of results
The methods used to describe the outcome of MDD and
the methods used to present the association with physicalelection.
Table 1
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hydrochloride
150-300 mg + IPT
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somatic scale
Median time to remission on HAMD-17
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usual (CAU) was only significant for
psychological presenters (P=.04).
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170 15.6% 8 weeks Fluoxetine 20 mg SCID-P SQ-SS Greater degree of somatic symptoms at
baseline predicts emergence of at least
one TRAE reported as moderate or
severe. (No correlation between SQ-SS
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this review. Outcome was presented as: time to a clinically
relevant response to treatment, probability of a clinically
relevant response, or mean change on a scale measuring
depressive symptoms. Also presented were the association
between physical symptoms and adherence to pharmaco-
therapy, or adverse effects of the treatment.
The outcome measures essentially reflected two types of
association between physical symptoms and MDD: they
either described the association between physical symptoms
and the outcome of MDD (Type A) or they described the
association between physical symptoms and adherence to
pharmacotherapy for MDD (Type B). These two types of
associations were analyzed separately.
The way in which the studies operationally defined
association varied considerably. This variation in outcome
assessment and data-presentation precluded an overall meta-
analysis because this would not provide meaningful
estimates of effect for one clinically relevant outcome
measure. Therefore, we performed a qualitative analysis and
presented a best-evidence synthesis. The number of studies
reporting on the association between physical symptoms and
the course of MDD, the consistency of the results, and the
methodological quality were taken into account. A priori,
findings were considered to be consistent if 75% or more of
the studies reporting on a factor showed the same direction of
the association. A study was considered to be of high quality
if it met 60% or more of the quality criteria described in the
first column of Table 2.
The definition of a level of evidence for the direction of
association was based on earlier methods used to summarize
the findings of observational research [13,17,18]. The level
of evidence could have one of the following values:
• Strong: consistent and statistically significant associa-
tions in at least two high-quality cohorts.
• Moderate: consistent and statistically significant asso-
ciation in one high-quality cohort and at least one low-
quality cohort.
• Weak: statistically significant association in one high-
quality cohort or consistent and statistically significant
in at least three low-quality cohorts.
• Inconclusive: association in less than three low-quality
cohorts, regardless of statistical significance.
• Inconsistent: inconsistent findings, irrespective of study
quality.
• Insufficient: only one study presenting non-statistical
significant association, irrespective of quality.Results
Study selection and characteristics
The searches in Medline, Psychinfo, and the Cochrane
Library yielded 2327 hits. All of the abstracts were written in
516 K.M.L. Huijbregts et al. / Journal of Psychosomatic Research 68 (2010) 511–519a language that could be interpreted by the authors. Nine
studies met the inclusion criteria.
The results of the searches are shown in a flowchart
(Fig. 1) that was designed according to the PRISMA
guidelines [19].
The characteristics of the studies that were included are
presented in Table 1.
Risk of bias
The results of the risk of bias assessment are presented in
Table 2.
Initial agreement between the assessors was reached in
69% of all cases. All differences in opinion were solved by
discussion, and consensus was reached in all cases.
The mean quality score was 66%, ranging from 50% to
87% (on average 10.6 out of 16 criteria were met). Five
studies had a high quality score (N60%). The criteria that
were most frequently not met were H (follow-up of at least
6 months) and J (information about completers vs. loss to
follow-up/drop outs).
Synthesis of results
The results are summarized in Table 1. The association
between physical symptoms and the outcomes of the nine
studies that were included could be combined to form two
types of association: the overall association between physical
symptoms and the course of MDD (type A) and the
association between physical symptoms and adherence to
pharmacotherapy and treatment-related adverse effects
(Type B). The last column of Table 1 refers to this type of
association. An overall level of evidence was determined for
both types, and is described in the text below.
Furthermore, a level of evidence was determined for the
sub-types that were used to determine the overall level of
evidence, namely the association of physical symptoms with
respectively: time to a clinically relevant response to
treatment, probability of a clinically relevant response, or
mean change on a scale measuring depressive symptoms.
These levels of evidence are also described below.
A. Association between physical symptoms and course
of MDD
Six studies reported on the association between physical
symptoms and the course of MDD. All six studies reported
a negative influence of these symptoms, and two studies
[23,24] had a high score for quality in our review. Both
reported statistically significant associations. Based on the
criteria for determining the level of evidence, the
conclusion is that there is strong evidence for a negative
overall association of physical symptoms with the course
of MDD.
As mentioned above, the overall association between
physical symptoms and course of MDD was composed of
three subtypes. The level of evidence for each of these sub-types is described below, as well as the strengths of these
associations in the individual studies. Two studies [20,21]
reported on the influence of physical symptoms on the time
to response to treatment, with results pointing in the same
direction. A high score on a scale measuring physical
symptoms at baseline predicted a 6.2-week longer time to
treatment response in one study [20] and a longer time to
onset of response in the other [21]. The duration was not
specified in the latter study. The level of evidence for the
association in terms of time to response, is inconclusive,
since one of the studies reported non-significant results [20]
and the other study [21] had a low score for quality.
Two other studies [22,23] reported on the influence of
physical symptoms on the probability of response to treatment.
Both demonstrated that a high score on a scale measuring
physical symptoms at baseline predicts a lower probability of a
good response. One of the studies [22] reported an OR of 2.29
on an unfavorable course for patients with physical symptoms
at baseline. The other study [23] reported a protective OR of a
low score on the SymptomsChecklist-90Revised (SCL-90-R)
somatic subscale [30]. This OR is a .96 per point decrease on
this scale. Therefore, a decrease, for instance, of 10 points on
this scale (ranging between 12 and 60) at baseline already
implies a protective OR of .61 on a favorable response. Since
the results of both studies are significant, but only one study
had a high score for quality [23], the level of evidence is
moderate for this association.
Finally, two studies [24,25] described a negative and
significant association between physical symptoms and
severity of depression at follow-up. One of the studies [24]
reported that, for patients with a physical presentation of
MDD at baseline, the decrease on a scale measuring the
severity of MDD was almost twice as much as for patients
with a psychological presentation. The other study [25]
reported a beta-coefficient of −.24, implying that a patient
who scores, for instance, 10 points higher on the somatic
scale of the SCL-90-R could expect a 2.4-point less decrease
on the HAMD-17. The level of evidence for the association
between physical symptoms and severity of depression is
moderate, since one of the studies had a high score for
quality and one study had a lower score for quality.
B. Association between physical symptoms and adherence
to pharmacotherapy and treatment-related adverse effects
Three studies [26–28] reported on the association
between physical symptoms and adherence to pharmaco-
therapy or treatment-related adverse effects. Two studies
[27,28] demonstrated a relationship between discontinua-
tion of medication and physical symptoms at baseline.
Only one of these studies had a high score for quality [27].
Since both studies reported statistically significant results,
the conclusion is that there is moderate evidence for a
negative association between physical symptoms and
adherence to pharmacotherapy.
One study [26] found that there was no correlation
between somatic scores on the SQ-SS and number of
Table 2





















A. Inception cohort (positive if interval
between diagnosis of depression and
baseline assessment was 6 weeks or less)
+ + + + + + + + ?
B. Description of study population (criteria
should be formulated for at least age,
gender and setting)
? + + + + + + + +
C. Definition of depression (depression
should be diagnosed using structured,
validated instruments)
+ + + + + + + + +
D. N≥100 + − − + + − + + −
Response/representativeness
E. Response rate in target population
(percentage of possibly eligible patients that
could be assessed for inclusion) ≥75%
? − − + + − ? + −
F. Information about non-responders vs.
responders in target population (positive if
information was presented about patient/
disease characteristics of responders
and non-responders)
? − ? − − ? ? − ?
Follow-up (extent and length)
G. Prospective data collection + + + + + + + + +
H. Follow-up of at least 6 months + − − − + − − − ?
I. Dropouts /loss to follow-up b20% + + ? − + − + − −
J. Information about completers vs. loss to
follow-up/drop-outs (patient/disease
characteristics such as age, gender and other
potential prognostic predictors)
? − − + − − − + −
Treatment
K. Description of treatment clearly described + + + + + + + + +
L. Standardized assessment of
depression outcome
+ + + + + + + + +
Prognostic factors/physical symptoms
M.Standardized assessment of physical
symptoms at baseline (symptoms should be
measured with a structured and validated
instrument and should not be limited to only
pain, fatigue or vital signs of MDD)
+ + + + + + + + +
Data presentation
N. Frequencies of most important outcome
measures (either frequency, percentage,
mean, median→interquartile range)
+ − − + + + − + +
O. Frequencies of physical symptom-scores
presented (either frequency, percentage,
mean, median→interquartile range)
? − − − + ? − + +
P. Influence of physical symptoms presented + + + + + + + + +
Total score per study→ 69% 56% 50% 75% 87% 56% 62% 81% 56%
517K.M.L. Huijbregts et al. / Journal of Psychosomatic Research 68 (2010) 511–519treatment-related adverse effects (TRAE) but that a
greater degree of somatic symptoms at baseline
predicted emergence of at least one TRAE reported as
moderate or severe. Since this is the only high quality
study reporting on this relationship, the evidence
remains weak.Discussion
Summary of evidence
All studies included in this systematic review indicated a
negative effect of physical symptoms on the prognosis of
518 K.M.L. Huijbregts et al. / Journal of Psychosomatic Research 68 (2010) 511–519MDD. Based on the consistency of this finding across the
available studies, the strength of the associations found, and
the quality of the studies, the overall level of evidence for
this association appears to be strong. The overall association
of physical symptoms was sub-divided in two types of
association: Type A, which refers to the association between
physical symptoms and the outcome of MDD, and Type B,
which refers to the association between physical symptoms
and adherence to pharmacotherapy for MDD. The evidence
for type A association appeared to be strong, and the
evidence for Type B association appeared to be moderate.
The findings for both types of association, and especially the
strong evidence for the overall association of physical
symptoms with a poorer prognosis of MDD, are important,
given the high comorbidity of physical symptoms with MDD
that is reported in the scientific literature [7,8].
Ideally one would like to pool the results of several
studies, reporting the size of the effect that concomitant
physical symptoms have on the prognosis of depression, but
given the small number of studies available and the variety of
methods and measures employed, calculating a meaningful
overall effect-size was not feasible. However, the available
studies do warrant the conclusion that the effect of
concomitant physical symptoms is both statistically and
clinically meaningful. There is reason to assume that this
effect might be substantial. One of the studies [24] reported
that for patients with a physical presentation of MDD at
baseline the decrease on a scale measuring the severity of
MDD was almost twice as much as for patients with a
psychological presentation. Two studies [22,23] reported OR
on an unfavorable course for patients with physical
symptoms at baseline. The first [22] reported an OR of
2.29 (CI 1.13–5.0). The second study [23] used another scale
to measure physical symptoms, the somatic scale of the SCL-
90-R. An odds ratio over a comparable difference in points
on this scale corresponds with an OR of 1.63 (CI 1.27–2.10).
The odds ratio thus appears to lie between 1.27 and 5.0,
implying that in the studies reporting OR [22,23] the
likelihood of an unfavorable course of MDDwas somewhere
between 1.27 and 5.0 times as high for patients suffering
from concomitant physical symptoms than for patients not
suffering from such symptoms. This is a rough estimate, but
it does show that the effect of physical symptoms on the
prognosis of MDD might be quite large. This suggests that
difficulty in translating efficacy findings to real-world
settings is associated with increased suffering from concom-
itant physical symptoms in patients with MDD.
Limitations and strengths of the study
Because of the importance of the subject under study, it is
somewhat puzzling that we could only find nine studies that
met our inclusion criteria. The fact that unpublished studies
were not available for consideration might possibly play a
role. Studies that did not find the effect we describe might
not have been published. Therefore, the conclusion of ourbest-evidence synthesis, i.e., that there seems to be strong
evidence for a negative association between physical
symptoms and the prognosis of MDD, is only a first step.
Evidently, more studies are needed in order to gain more
insight into the phenomenon.
Future studies could focus on effect-modification by
physical symptoms of specific types of treatment for MDD.
In particular, trials evaluating the effect of physical
symptoms on psychotherapy could provide more insight.
Studies which include a clinical assessment as to whether or
not the physical symptoms that depressed patients experi-
ence are medically unexplained would also be welcome.
From the studies included in this review we were unable to
make such a distinction. An overview of scales to assess
physical symptoms, that could be included in baseline
questionnaires, is provided by Hiller and Janca [31].
Conclusions and implication for daily practice
Based on our results, a few recommendations can be made
for daily clinical practice. Given the evidence for quite strong
associations between physical symptoms and subsequent
prognosis of depression, comorbid physical symptoms should
be assessed systematically in depressed patients. Since both
adherence to pharmacotherapy [27,28] and outcome seem to
be negatively affected [26], specific attention should be paid
to physical symptoms -both explained and unexplained- in
patients suffering from depression.
Effective treatment for MDD in the co-occurrence of
physical symptoms may require collaboration between
different health care professionals. The experiences in
primary care with the collaborative care model are promising
in this respect, since this method of organizing co-operation
between health care professionals has been found to be
effective in the treatment of both MDD [32] and persistent
medically unexplained symptoms [33].
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the AND operatorKey words and medical subject
headings within categories
combined with the OR operatorInformation on the outcome or
course of the disorderRemission, relapse, outcome, prognosis,
remit*, recur*, effectiv*, efficacy,
recurrence, treatment outcome,
residual symptomDesign Clinical trial, trial, epidemiologic studies,
epidemiologic, epidemiology, prognos*,
prognosis, predictionPhysical symptoms 102 symptoms and symptom-related
keywords were entered into this category,
ranging from pain and fatigue to
somatoform disorders, keywords such as
somatization or somatization, to
symptoms such as headache, nausea
and gas.Combined with NOT category Diabetes, neoplasms, cardiovascular
diseases, lung diseases, obstructive
pulmonary diseasesRef citations were unsequence and with citations in Tables (unsequence
table citations).
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